SCHEMBL13342736

SCHEMBL13342736

CCCCC(=O)Oc1ccc(Cl)cc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
KDM4E B2RXH2 3/20 0.51
ALOX15 P16050 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 1/20 0.51
HIF1A Q16665 1/20 0.51
TP53 P04637 1/20 0.51
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50
MAPT P10636 3/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11035732 0.95 GAA (0.56) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL13342738 0.94 GAA (0.55) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL3837266 0.91 CYP1A2 (0.54) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL15548006 0.88 ALOX15 (0.57) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL27866069 0.87 NPSR1 (0.53) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL27846924 0.84 L3MBTL1 (0.54) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL28414795 0.84 KDM4E (0.48) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL9799902 0.84 CYP1A2 (0.56) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL3834865 0.84 CYP1A2 (0.56) GAAMEN1KMT2AKDM4EALOX15
SCHEMBL15546921 0.83 ALOX15 (0.63) GAAMEN1KMT2AKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1512397-B1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2014-10-08 EP disclosed
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 US disclosed
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES RELA, NFKBIA, NFE2 GAA 967/4885MEN1 4814/4885KMT2A 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.